---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208999"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:52:20.835856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026

## Summary
- Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
- Cash and equivalents $106.9M as of Mar 31, 2026, up from $89.2M at Dec 31, 2025.
- Received $5M milestone payment from Boehringer Ingelheim in April 2026 for SZN-413 GLP toxicology study progress.
- On track to submit IND for SZN-8141 for retinal diseases in H2 2026; preclinical data presented at ARVO.
- R&D expenses $9.3M (up $2.7M YoY) due to ophthalmology program costs; G&A $6.1M (up $2.1M).

## SEC filing metadata
- accession: 0001193125-26-208999
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/0001193125-26-208999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/srzn-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208999
- JSON: https://secwatch.observer/filing/0001193125-26-208999.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208999.txt

## Source-grounded claims
- claim_id: d8c6797677cdb84f2e04a8e4fc6b95af2ed7799a
  claim: Surrozen, Inc./DE reported the quarter ended March 31, 2026 results: net income $127.5 million, EPS ($11.65) per share.
  evidence_excerpt: Net loss was $127.5 million, or ($11.65) per share for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/0001193125-26-208999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.